Trial Profile
A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Seizures
- Focus Therapeutic Use
- Sponsors Radius Pharmaceuticals
- 11 Nov 2020 Status changed from recruiting to discontinued.
- 03 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Jun 2019.
- 03 Jun 2019 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.